위암 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global gastric cancer market size is expected to reach USD 15.98 Billion in 2034 from USD 6.33 Billion in 2025, growing at a CAGR of 10.84% during 2026-2034.This market is gaining importance as healthcare systems continue to address the burden of gastric cancer through improved diagnosis, treatment, and disease management. Gastric cancer develops in the stomach and can be influenced by factors such as Helicobacter pylori infection, smoking, dietary habits, and certain genetic predispositions. Growing awareness of cancer symptoms, increasing access to diagnostic procedures, and improvements in medical imaging are supporting efforts to identify the disease. Greater attention to cancer screening and early diagnosis in high-risk populations is also encouraging healthcare providers to strengthen detection and treatment pathways.

Market growth is driven by advancements in oncology treatments, increasing investment in cancer research, and the development of targeted therapies and immunotherapies. Healthcare institutions are adopting improved diagnostic approaches, including endoscopy, biopsy, and molecular testing, to support disease classification and treatment planning. Pharmaceutical companies are investigating therapies that target specific tumor characteristics and immune pathways. The growing use of biomarkers is also helping clinicians identify patients who may benefit from particular treatment options. In addition, expanding oncology infrastructure and improved access to specialist care are supporting the availability of gastric cancer management services in different regions.

The future prospects of this market will be shaped by advances in early detection, personalized treatment, and innovative cancer therapies. Research into molecular biomarkers may improve patient selection for targeted treatments and immunotherapy. Improvements in diagnostic technologies and greater awareness of risk factors could support earlier identification of the disease. Combination therapies and precision oncology approaches may also create new treatment opportunities. However, late-stage diagnosis, treatment costs, and differences in healthcare access remain important challenges. Continued research, improved clinical pathways, and broader availability of specialized oncology services will be essential for strengthening patient outcomes.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease Type

• Adenocarcinoma
• Lymphoma
• Gastrointestinal Stromal Tumor
• Carcinoid Tumor
• Others

By Treatment Type

• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Radiation Therapy And Surgery

By Drug Class

• PD-1/PD-L1 Inhibitors
• HER2 Antagonists
• VEGFR2 Antagonists
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Specialty And Retail Pharmacies
• Hospital Pharmacies
• Others

COMPANIES PROFILED

• Merck & Co., Bristol Myers Squibb, AstraZeneca, Astellas Pharma, Roche, Eli Lilly, BeiGene, Daiichi Sankyo, Zymeworks, Amgen, Novartis, Pfizer, Sanofi, Takeda, Servier, Jiangsu Hengrui Medicine, Innovent Biologics, Eisai, Regeneron, Jiangsu Chia Tai Tianqing

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTRIC CANCER MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Adenocarcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Gastrointestinal Stromal Tumor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Carcinoid Tumor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTRIC CANCER MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Radiation Therapy And Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTRIC CANCER MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Class
• 6.2. PD-1/PD-L1 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. HER2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. VEGFR2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTRIC CANCER MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GASTRIC CANCER MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Specialty And Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL GASTRIC CANCER MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Disease Type
  • 9.2.2 By Treatment Type
  • 9.2.3 By Drug Class
  • 9.2.4 By Route Of Administration
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Disease Type
  • 9.3.2 By Treatment Type
  • 9.3.3 By Drug Class
  • 9.3.4 By Route Of Administration
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Spain
  • 9.3.11 Russia
  • 9.3.12 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Disease Type
  • 9.4.2 By Treatment Type
  • 9.4.3 By Drug Class
  • 9.4.4 By Route Of Administration
  • 9.4.5 By Distribution Channel
  • 9.4.6 China
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 India
  • 9.4.10 Australia
  • 9.4.11 South East Asia
  • 9.4.12 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Disease Type
  • 9.5.2 By Treatment Type
  • 9.5.3 By Drug Class
  • 9.5.4 By Route Of Administration
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Disease Type
  • 9.6.2 By Treatment Type
  • 9.6.3 By Drug Class
  • 9.6.4 By Route Of Administration
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL GASTRIC CANCER INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Merck & Co
  • 11.2.2 Bristol Myers Squibb
  • 11.2.3 AstraZeneca
  • 11.2.4 Astellas Pharma
  • 11.2.5 Roche
  • 11.2.6 Eli Lilly
  • 11.2.7 BeiGene
  • 11.2.8 Daiichi Sankyo
  • 11.2.9 Zymeworks
  • 11.2.10 Amgen
  • 11.2.11 Novartis
  • 11.2.12 Pfizer
  • 11.2.13 Sanofi
  • 11.2.14 Takeda
  • 11.2.15 Servier
  • 11.2.16 Jiangsu Hengrui Medicine
  • 11.2.17 Innovent Biologics
  • 11.2.18 Eisai
  • 11.2.19 Regeneron
  • 11.2.20 Jiangsu Chia Tai Tianqing